Navigation Links
iCardiac Expands Sales and Marketing Team
Date:8/6/2009

Adds Industry Veteran with Over Two Decades of Cardiovascular Core Lab Experience

Rochester, NY (PRWEB) August 6, 2009 -- iCardiac Technologies, Inc., a leader in advanced cardiac safety ECG services and automated QT analysis, announced that it has expanded its sales and marketing team by hiring Susan Boyle as Senior Director of Business Development. Ms. Boyle has over two decades of experience in operations and business development in the clinical research industry, specializing in centralized cardiovascular diagnostic services at a number of leading core laboratories.

"We are excited to welcome Susan to the iCardiac team," said Sasha Latypova, Executive Vice President. "Susan's deep client relationships and long history of successfully partnering with clinical pharmacology units will allow iCardiac to better serve its rapidly broadening set of customers and channel relationships."

"I am proud to join iCardiac at this exciting transformation point in the cardiac core laboratory industry," said Ms. Boyle. "iCardiac has driven a dramatic shift in the industry by establishing the company as both a leader in Highly Automated QT evaluation as well as advanced techniques for avoiding false positives and negatives in cardiac safety studies."

About iCardiac Technologies
iCardiac Technologies, Inc. is a technologically differentiated cardiac core lab providing expert scientific consultation, end-to-end project management, statistical analysis and the industry's most sophisticated FDA-accepted cardiac safety assessment methodologies. iCardiac's analysis service provides drug developers with more precise and cost-effective methods for ECG/QT interval measurements, including Highly Automated QT, which has been validated by pharmaceutical companies and is now used in regulatory submissions as equivalent to the manual evaluation of ECGs in Thorough QT studies. In addition, iCardiac provides Beyond QT, a suite of advanced ECG-based cardiac safety markers that have been accepted and used as secondary end-points by the regulators, and deliver a more accurate assessment of the cardiac safety profile of drugs in development. iCardiac's COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large and medium sized pharmaceutical, biotechnology, and medical device companies. For more information, visit: www.icardiac.com.

# # #

Read the full story at http://www.prweb.com/releases/icardiac/business/prweb2715644.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. iCardiac Reports Significant Revenue Growth and Profitability
2. iCardiac Applies Advanced Cardiac Safety Biomarkers in Clinical Study for Top Pharmaceutical Company
3. iCardiac Selected for Multiple Cardiac Safety Studies
4. iCardiac Selected by Top 10 Pharmaceutical Company
5. iCardiac Processes Volume of Data Equivalent to One Thousand Traditional Thorough QT Studies
6. ATS Medical Expands Open Pivot Heart Valve Offerings
7. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
8. BioLife Solutions Expands Scientific Advisory Board
9. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
10. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
11. Pharsight Expands Strategic Consulting Services Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... 2017 According to a new market research report "In ... Disease), & End User (Molecular Diagnostic Laboratories, Academic and Research Institutions) - Global ... 739.9 Million by 2021 from USD 557.1 Million in 2016, growing at a ... ... MarketsandMarkets Logo ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... Clinical Ops Executives 2017 in its continued commitment to the advancement of the ... to discuss current issues related to clinical trial planning and management. , ...
(Date:1/18/2017)... ... January 18, 2017 , ... MYOLYN, which ... it has submitted a 510(k) to the FDA, requesting clearance of the MyoCycle ... electrical stimulation (FES) technology. , The submission marks a major milestone for ...
(Date:1/18/2017)... CA (PRWEB) , ... January 18, 2017 , ... ... report the publishing of the latest paper by its Science Editor, Dr. Elisabeth ... (Nederlands Tijdschrift voor Medische Microbiologie). Dr. Bik joined uBiome in October 2016 from ...
Breaking Biology Technology:
(Date:12/15/2016)... 2016  There is much more to innovative access ... engine. Continental will demonstrate the intelligence of today,s solutions ... . Through the combination of the keyless entry and ... elements, the international technology company is opening up new ... "The integration of biometric elements brings our ...
(Date:12/8/2016)... -- Market Research Future published a half cooked research report on ... and Service Market is expected to grow over the CAGR of ... ... Mobile Biometric Security and Service Market is increasing ... authentication and security from unwanted cyber threats. The increasing use of ...
(Date:12/7/2016)... -- BioCatch , the global leader in behavioral biometrics, ... grew to over 40 granted and pending patents. ... , , The Company,s IP ... System, Device, and Method Estimating Force Applied to a Touch Surface, ... costly hardware components needed to estimate the force and pressure applied to ...
Breaking Biology News(10 mins):